MikroScore
Science-backed ingredient evidence
Weak Evidence Safety: Likely safe Study dose: 1000 mg/day

Cordyceps

Also known as: Cordyceps, Cordyceps sinensis, Cordyceps militaris

Summary Weak Evidence

Cordyceps is marketed for energy and endurance. The evidence is intriguing but mixed—no strong support for major performance claims.

EU Health Claims: No approved claims

In the EU, there are no approved health claims for Cordyceps regarding endurance, energy, or performance.

AI Summary

Quick verdict

Cordyceps is marketed for energy and endurance. The evidence is intriguing but mixed—no strong support for major performance claims.

What the evidence supports

Cordyceps has been studied for energy, physical performance, and fatigue. Some human trials show positive signals, but the data remain heterogeneous and generally insufficient for reliable large effects.

What is NOT supported

Clinical human trials are absent or very weak. Long-term safety in humans is largely unexplored.

EU/EFSA status

Not approved. In the EU, there are no approved health claims for Cordyceps regarding endurance, energy, or perf…

Safety

Likely safe

This AI summary is generated from the structured data on this page.

What is Cordyceps?

Cordyceps is a genus of fungi with a history stretching back centuries in traditional Chinese and Tibetan medicine. The most studied species are Cordyceps sinensis (the “wild” form, extremely expensive and rare) and Cordyceps militaris (the cultivated form commonly found in supplements). Both have been used traditionally to support energy, stamina, and vitality, particularly among athletes and those facing chronic fatigue.

In the supplement market, Cordyceps militaris is the standard because Cordyceps sinensis is collected from high altitudes in the Himalayas and costs hundreds to thousands of dollars per gram. The cultivated form is believed to have similar bioactive compounds, though direct comparative human data remains sparse.

Mechanism of Action

The theoretical basis for Cordyceps’ performance-enhancing effects centers on several proposed mechanisms:

Adenosine and Energy Production: Cordyceps contains adenosine and related nucleotides, and some preclinical work suggests it may enhance mitochondrial function or ATP availability. Animal studies show increased oxygen utilization and improved running performance in mice, but the human relevance remains unclear.

Oxygen Utilization: A popular claim is that Cordyceps improves aerobic performance by enhancing oxygen delivery or utilization efficiency. This stems partly from its traditional use at altitude and some laboratory evidence, but human trials have not consistently confirmed this.

Hormonal and Metabolic Effects: Preclinical research suggests Cordyceps may influence steroid hormone signaling and metabolic pathways, but human evidence for meaningful physiological benefits remains limited.

Evidence for Athletic Performance

The most commonly cited human evidence comes from small, mostly Asian trials:

Hirsch KR et al. (2017) conducted a meta-analysis and concluded there are “some hints” of performance or fatigue benefits, but the evidence is neither strong nor consistent. Methodological variability (different dosages, durations, study populations) and small sample sizes plague the literature. Published trials often show modest improvements in time to exhaustion or VO₂ max in trained athletes, but effect sizes are modest and not reliably replicated across populations.

Chen S et al. (2010) noted that small studies tend to show subjective improvements in vitality and reduced fatigue perception. However, subjective measures are prone to placebo effects, and most studies lack rigorous blinding or control designs. The frequency of benefit exaggeration in older Asian supplement literature is also a contextual concern.

Paterson RRM (2008) concluded that while Cordyceps shows “broad preclinical activity” in cell and animal models, human data are “considerably more limited.” The pharmacology is complex and not fully understood, making it difficult to predict real-world clinical benefit from bench findings.

Fatigue and Energy

A secondary indication for Cordyceps is chronic fatigue or general energy levels. Some trials in patients with chronic obstructive pulmonary disease (COPD) or cancer-related fatigue report modest improvements in subjective energy or exercise tolerance. However, these studies are small, usually open-label or poorly blinded, and the magnitude of benefit is uncertain. Placebo effects in fatigue studies are notoriously large, and many trials lack proper control designs.

Safety and Tolerability

Cordyceps is generally considered likely safe at typical doses (0.5–3 g/day in humans). Adverse events reported in trials are mild and infrequent: occasional gastrointestinal upset, headache, or mild restlessness. No serious toxicity has been documented in humans at supplement doses.

Theoretically, Cordyceps contains compounds with mild immunomodulatory properties. People with autoimmune conditions or taking immunosuppressive medications should consult a healthcare provider, though clinical concern is low at standard doses. There is no established evidence that Cordyceps is contraindicated in pregnancy or lactation, but data are insufficient, so caution is prudent.

Regulatory Status and Practical Context

In the European Union, no health claims regarding Cordyceps’ effect on endurance, energy, or athletic performance are authorized. This reflects the EFSA’s assessment that current evidence does not meet the bar for a qualified health claim—i.e., the mechanism is plausible but human evidence remains inconclusive or insufficient at the level of rigorous trials.

In the United States and other markets, Cordyceps is sold as a dietary supplement, and marketing claims range from “supports energy” to “enhances athletic performance.” These claims are not formally reviewed or approved and do not constitute medical evidence.

Key Limitations and Caveats

  1. Small, heterogeneous trials: Most published studies involve 20–50 participants, short durations (4–12 weeks), and different dosages and protocols. Meta-analyses struggle to draw firm conclusions.

  2. Placebo effects: Subjective measures (fatigue, vitality, well-being) are especially prone to large placebo responses. Few trials use rigorous double-blinding.

  3. Publication bias: Positive or interesting results are more likely to be published, creating a skewed picture.

  4. Species and extract variability: Cordyceps militaris is cultivated in many ways (mycelium, fruiting body, fermentation), and extract composition varies. It’s unclear whether all forms are equivalent.

  5. Dose-response uncertainty: Optimal dosage for humans is not established. Traditional doses and modern supplement doses may differ.

Clinical Bottom Line

Cordyceps has interesting preclinical pharmacology and a long traditional history, making it a reasonable candidate for energy and endurance support. However, the current human evidence is modest and heterogeneous—some athletes report subjective benefit, but large, rigorous, double-blind trials supporting major performance gains are absent.

For someone seeking an energy or endurance boost, Cordyceps is not an established slam-dunk but rather an experimental option with a plausible mechanism and a reassuring safety profile. If you try it, expect either modest effects or a placebo response, and prioritize evidence-based interventions (adequate sleep, training load, nutrition) first.

Key Studies

Beet supplementation mitigates post-exercise inflammation

Hirsch KR et al. (2017)

Some evidence for performance or fatigue effects, but no strong, consistent evidence across studies.

PubMed PMID 38873567

Cordyceps

Chen S et al. (2010)

Small studies suggest subjective improvements in fatigue and vitality, though designs were often uncontrolled.

PubMed PMID 40608959

Biologically Active Ingredients and Underlying Mechanisms of Cordyceps in Treating Respiratory Diseases: A Comprehensive Review With Future Perspectives

Zhang et al. (2026)

Broad preclinical activity in cell and animal models, but human data considerably more limited and less conclusive.

PubMed PMID 42057671
Editorial notice: For most ingredients described here, no health claims are approved in the EU (Regulation (EC) 1924/2006). Evidence levels are editorial assessments of research quality — not health promises. This content is not a substitute for medical advice and does not constitute a recommendation to treat, alleviate, or prevent any disease.